• Explore /
  • Poster
  • / First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.

First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.

Abstract Poster

Authors

null

Zev A. Wainberg

David Geffen School of Medicine at UCLA, Los Angeles, CA

Zev A. Wainberg , Kai-Keen Shiu , Fernando Rivera , Louise C. Medley , Morteza Aghmesheh , Richard Francis Dunne , Rajarshi Roy , Lucjan S. Wyrwicz , Timothy Larson , Jean-Philippe Metges , Wasat Mansoor , Eray Goekkurt , Luiz Carlos Moreira Antunes , Victor Castro Oliden , Erin Jensen , Sukrut Shah , Sonal Bordia , Pooja Bhagia , Maeve Aine Lowery

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03189719 and NCT03675737

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 345)

DOI

10.1200/JCO.2024.42.3_suppl.345

Abstract #

345

Poster Bd #

G6

Abstract Disclosures

Similar Posters

First Author: Sun Young Rha

First Author: Yelena Y. Janjigian

First Author: Ryan Sugarman

First Author: Zev A. Wainberg